Vital Therapies, Inc. (NASDAQ:VTL) Director Jean Jacques Bienaime purchased 10,000 shares of Vital Therapies stock in a transaction that occurred on Wednesday, September 13th. The stock was acquired at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the transaction, the director now directly owns 65,119 shares of the company’s stock, valued at approximately $260,476. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Vital Therapies, Inc. (VTL) traded up 3.70% on Thursday, reaching $4.20. 535,405 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $3.01 and a 200-day moving average price of $3.36. Vital Therapies, Inc. has a 52 week low of $2.25 and a 52 week high of $6.58. The stock’s market capitalization is $177.27 million.

Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. During the same period last year, the company earned ($0.30) earnings per share. On average, analysts predict that Vital Therapies, Inc. will post ($1.31) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Insider Buying: Vital Therapies, Inc. (VTL) Director Buys 10,000 Shares of Stock” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/insider-buying-vital-therapies-inc-vtl-director-buys-10000-shares-of-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of VTL. FMR LLC increased its stake in shares of Vital Therapies by 102.9% in the 1st quarter. FMR LLC now owns 2,957,878 shares of the company’s stock worth $11,832,000 after acquiring an additional 1,500,000 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Vital Therapies by 9.6% in the 1st quarter. Victory Capital Management Inc. now owns 2,549,439 shares of the company’s stock worth $10,197,000 after acquiring an additional 222,824 shares during the last quarter. UBS Oconnor LLC acquired a new stake in shares of Vital Therapies in the 1st quarter worth $800,000. Goldman Sachs Group Inc. increased its stake in shares of Vital Therapies by 261.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after acquiring an additional 168,705 shares during the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Vital Therapies in the 2nd quarter worth $396,000. 25.58% of the stock is owned by institutional investors and hedge funds.

Several research analysts have commented on the stock. Raymond James Financial, Inc. assumed coverage on shares of Vital Therapies in a research note on Thursday, May 18th. They set an “outperform” rating and a $6.00 price objective for the company. ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.